EUVIMEDEUVIMED entdecken
Crossref

Safety of dual antiplatelet therapy in the acute phase of aneurysmal subarachnoid hemorrhage: a propensity score–matched study

Farid Qoorchi Moheb Seraj, Mohammad Hossein Mirbolouk, Marjan Vaezi, Feizollah Ebrahimnia, Reza Gorji, Sajjad Najafi, Hashem Pahlavan Shamsi, Ali Sadeghian Shahi, Payam Sasannejad, Samira Zabihyan, Ashkan Mowla, Daniel Kheradmand und 1 weitere

Neurosurgical Focus · 2023-10 · 55 (4) · E10

DOI: 10.3171/2023.7.focus23376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Focus, 2023-10. Verfasst von Farid Qoorchi Moheb Seraj und 12 weiteren Autor:innen. Beteiligte Einrichtung: 1Neurosurgical Department, Neurovascular Section, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Subarachnoid Hemorrhage, Vasospasm, Intracranial, Aneurysm, Ruptured, Brain Ischemia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE With the evolution of neuroendovascular treatments, there is a great trend to treat acutely ruptured wide-necked aneurysms with stent-assisted coiling (SAC) and flow diverters (FDs), which inevitably requires dual antiplatelet therapy (DAPT). This therapy can increase the rate of hemorrhagic complications following other neurosurgical maneuvers, such as external ventricular drain (EVD) placement or removal. In this study, the authors aimed to evaluate the safety of DAPT in patients with aneurysmal subarachnoid hemorrhage (SAH) treated with SAC or FDs and the therapy’s potential benefit in reducing cerebral ischemia and cerebral vasospasm. METHODS In this retrospective study, the authors reviewed the records of patients who had been admitted to their hospital with acute aneurysmal SAH and treated with SAC, FDs, and/or coiling between 2012 and 2022. Patients were classified into two groups: a DAPT group, including patients who had received DAPT for SAC or FDs, and a non-DAPT group, including patients who had not received any antiplatelet regimen and had been treated with coiling. Perioperative hemorrhagic and ischemic complications and clinical outcomes were compared between the two groups. RESULTS From among 938 cases of acute ruptured aneurysms treated during 10 years of study, 192 patients were included in this analysis, with 96 patients in each treatment group, after propensity score matching. All basic clinical and imaging characteristics were equivalent between the two groups except for the neck size of aneurysms (p < 0.001). EVD-related hemorrhage was significantly higher in the DAPT group than in the non-DAPT group (p = 0.035). In most patients, however, the EVD-related hemorrhage was insignificant. Parent artery or stent-induced thrombosis was higher in the DAPT group than in the non-DAPT group (p = 0.003). The rate of cerebral ischemia was slightly lower in the DAPT group than in the non-DAPT group (11.5% vs 15.6%, p = 0.399). In the multivariate analysis, cerebral ischemia, rebleeding before securing the aneurysm, extracranial hemorrhage, and cerebral vasospasm were the predictive factors of a poor clinical outcome (p < 0.001, p < 0.001, p = 0.038, and p = 0.038, respectively). CONCLUSIONS The DAPT regimen may be safe in the setting of acute aneurysmal SAH. Although EVD-related hemorrhage is more common in the DAPT group than the non-DAPT group, it is usually insignificant without any neurological deficit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Subarachnoid HemorrhageVasospasm, IntracranialAneurysm, RupturedBrain IschemiaEmbolization, TherapeuticIntracranial AneurysmHumansPlatelet Aggregation InhibitorsRetrospective StudiesPropensity ScoreStentsTreatment Outcome

Stichwörter der Autor:innen

dual antiplateletsflow diverterruptured aneurysmstent-assisted coilingsubarachnoid hemorrhage

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • 1Neurosurgical Department, Neurovascular Section, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • 2Department of Neurosurgery, Firouzgar Hospital, Iran University of Medical Sciences, School of Medicine, Tehran, Iran.
  • 3Department of Neurosurgery, Emam Hospital, Mazandaran University of Medical Sciences, School of Medicine, Sari, Iran.
  • 4Department of Neurological Surgery, Division of Stroke and Endovascular Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California; and.
  • 5Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.

Zitieren

APA

Qoorchi Moheb Seraj, F., Mirbolouk, M. H., Vaezi, M., Ebrahimnia, F., Gorji, R., Najafi, S., Pahlavan Shamsi, H., Sadeghian Shahi, A., Sasannejad, P., Zabihyan, S., Mowla, A., Kheradmand, D., & Baharvahdat, H. (2023). Safety of dual antiplatelet therapy in the acute phase of aneurysmal subarachnoid hemorrhage: a propensity score–matched study. Neurosurgical Focus, 55(4), E10. https://doi.org/10.3171/2023.7.focus23376

Vancouver

Qoorchi Moheb Seraj F, Mirbolouk MH, Vaezi M, Ebrahimnia F, Gorji R, Najafi S, et al. Safety of dual antiplatelet therapy in the acute phase of aneurysmal subarachnoid hemorrhage: a propensity score–matched study. Neurosurgical Focus. 2023;55(4):E10. doi:10.3171/2023.7.focus23376

BibTeX
@article{QoorchiMohebSeraj2023,
  author = {Qoorchi Moheb Seraj, Farid and Mirbolouk, Mohammad Hossein and Vaezi, Marjan and Ebrahimnia, Feizollah and Gorji, Reza and Najafi, Sajjad and Pahlavan Shamsi, Hashem and Sadeghian Shahi, Ali and Sasannejad, Payam and Zabihyan, Samira and Mowla, Ashkan and Kheradmand, Daniel and Baharvahdat, Humain},
  title = {Safety of dual antiplatelet therapy in the acute phase of aneurysmal subarachnoid hemorrhage: a propensity score–matched study},
  journal = {Neurosurgical Focus},
  year = {2023},
  volume = {55},
  number = {4},
  pages = {E10},
  doi = {10.3171/2023.7.focus23376}
}
Kostenlos starten →